Search Result

Results for "

IRAK kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IRAK (45) AAK1 (1) Apoptosis (3) Bcr-Abl (1) CDK (3) Cyclic GMP-AMP Synthase (1) Cyclin G-associated Kinase (GAK) (1) Enolase (1) Ephrin Receptor (1) FGFR (1) FLT3 (2) IFNAR (1) Interleukin Related (1) Itk (1) JAK (2) Ligands for Target Protein for PROTAC (1) MAP3K (2) MAP4K (3) MELK (1) NADH Dehydrogenase (1) NF-κB (3) p38 MAPK (1) Pim (1) PROTACs (6) Reference Standards (4) Src (1) STAT (2) TNF Receptor (2) Toll-like Receptor (TLR) (1) Trk Receptor (1) ULK (1) Wee1 (1)
By Research Areas:	Cancer (20) Infection (6) Inflammation/Immunology (35) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	PROTAC Synthesis (1)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Click Chemistry

Targets Recommended: IRAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103490

Takinib Maximum Cited Publications 28 Publications Verification EDHS-206	MAP3K Apoptosis	Infection Inflammation/Immunology Cancer
Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC₅₀=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (K_D(app) of 0.46 μM) .

HY-19836

Zimlovisertib 5+ Cited Publications PF-06650833	IRAK	Inflammation/Immunology
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC₅₀s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas .

HY-103017A

JH-X-119-01 5+ Cited Publications	IRAK	Infection Inflammation/Immunology Cancer
JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC₅₀ of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .

HY-139374

Zabedosertib 2 Publications Verification BAY 1834845	IRAK	Inflammation/Immunology
Zabedosertib (BAY 1834845) is a selective, orally active *IRAK4* inhibitor with immunomodulatory potential, IC₅₀ is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .

HY-13329

IRAK-1-4 Inhibitor I 5+ Cited Publications IRAK-1/4 Inhibitor I	IRAK	Inflammation/Immunology
IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC₅₀s of 0.2 μM and 0.3 μM, respectively.

HY-111101

AZ1495	IRAK	Cancer
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 *(IRAK4)* inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC₅₀ values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K_d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-101922

IRAK4-IN-1	IRAK	Inflammation/Immunology
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-114181

IRAK4-IN-4 1 Publications Verification	IRAK Cyclic GMP-AMP Synthase	Inflammation/Immunology
IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .

HY-103017

JH-X-119-01 hydrochloride 5+ Cited Publications	IRAK	Infection
JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice .

HY-137342

SB1-G-187	PROTACs Src IRAK Bcr-Abl MAP4K Cyclin G-associated Kinase (GAK) CDK	Cancer
SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, *IRAK1* and LYN. SB1-G-187 induces degradation of target kinases via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker) .

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .

HY-109585

IRAK4-IN-7	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .

HY-W722277A

LCC-12 formate	Interleukin Related NADH Dehydrogenase TNF Receptor JAK STAT IRAK	Inflammation/Immunology
LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α levels, as well as JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture .

HY-148238

GNE-2256	IRAK	Inflammation/Immunology
GNE-2256 (molecule 19), a chemical probe, is an orally active *IRAK4* (*Interleukin 1 receptor associated kinase* 4*) inhibitor (IRAK4 K_i=1.4 nM; IL-6 IC₅₀*=190 nM) .

HY-123854

PF-06426779	IRAK	Inflammation/Immunology
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor associated kinase 4 (IRAK4), with an IC₅₀ of 0.3 nM .

HY-13276

IRAK inhibitor 2	IRAK	Inflammation/Immunology
IRAK inhibitor 2 is an interleukin-1 receptor-associated kinase (IRAK) inhibitor. IRAK inhibitor 2 can be used for the research of inflammatory and immune diseases .

HY-77048

IRAK-4 protein kinase inhibitor 2	IRAK	Inflammation/Immunology
IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC₅₀ of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .

HY-159953

IRAK1/4/pan-FLT3 Kinase-IN-1	IRAK FLT3	Inflammation/Immunology Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 is an orally active, potent and selective *IRAK/pan-FLT3* *kinase* inhibitor with IC₅₀s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively. IRAK1/4/pan-FLT3 Kinase-IN-1 can be used for research on AML .

HY-P5432

IRAK-4 Peptide substrate IRAK-1 (360-380)	IRAK	Others
IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)

HY-134911

HS-243	IRAK CDK	Inflammation/Immunology Cancer
HS-243 is a potent and selective *IRAK-4* and *IRAK-1* inhibitor, with IC₅₀ values of 20 and 24 nM. HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC₅₀ of 0.5 μM. HS-243 shows anti-inflammatory and anticancer activity .

HY-179094

PSP-0119	PROTACs IRAK NF-κB Enolase	Inflammation/Immunology Cancer
PSP-0119 is a highly efficient and effective PROTAC degrader targeting *IRAK4* (IC₅₀ = 2.83 nM). PSP-0119 can inhibit *IRAK4* kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) .

HY-129967

PROTAC IRAK4 ligand-1	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-13278

IRAK inhibitor 4 1 Publications Verification	IRAK	Inflammation/Immunology
IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

HY-13280

IRAK inhibitor 6	IRAK	Inflammation/Immunology
IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC₅₀ of 160 nM.

HY-13277

IRAK inhibitor 3 1 Publications Verification	IRAK	Inflammation/Immunology
IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.

HY-139315

PROTAC IRAK4 degrader-4	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .

HY-177515

IRAK4 modulator-2	IRAK STAT JAK NF-κB	Inflammation/Immunology
IRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and *IRAK1* inhibitor with IC₅₀ values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease .

HY-E70731

**IRAK4 aa104-460 Recombinant Human Active Protein Kinase**	IRAK	Inflammation/Immunology
The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 aa104-460 Recombinant Human Active Protein Kinase is a recombinant IRAK4 aa104-460 protein that can be used to study IRAK4 aa104-460-related functions .

HY-13278A

IRAK inhibitor 4 (trans)	IRAK	Inflammation/Immunology
IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.

HY-174843

IRAK4-IN-32	IRAK	Inflammation/Immunology
IRAK4-IN-32 (Compound 10) is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an enzymatic IC₅₀ value of 18.86 nM and a cellular IC₅₀ value of 6.19 nM. IRAK4-IN-32 is promising for research of inflammatory and autoimmune diseases .

HY-150733

IRAK4-IN-19	IRAK	Inflammation/Immunology
IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease .

HY-150593

IRAK4-IN-16	IRAK	Cancer
IRAK4-IN-16 (compound 4) is a potent *IRAK4* (interleukin-1 receptor associated kinase 4) inhibitor, with an IC₅₀ of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC₅₀ values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .

HY-139317

PROTAC IRAK4 degrader-6	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .

HY-161620

DW18134	IRAK	Inflammation/Immunology
DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC₅₀ of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .

HY-169057

BI1543673	IRAK Toll-like Receptor (TLR)	Inflammation/Immunology
BI1543673 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. BI1543673 can reduce the inflammatory response stimulated by TLR4 and TLR7/8 in human lung tissue. BI1543673 can decrease inflammatory signaling in a mouse model of lung inflammation induced by LPS .

HY-158374

BIO-8169	IRAK	Inflammation/Immunology
BIO-8169 is a selective inhibitor for interleukin receptor-associated kinase 4 (IRAK 4), with an IC₅₀ of 0.23 nM. BIO-8169 exhibits good pharmacokinetic character, reduces the production of pro-inflammatory cytokines, and attenuates the autoimmune encephalomyelitis in EAE mice model. BIO-8169 exhibits good blood brain penetrant with a rat Kpu,u of 0.7 .

HY-176410

IRAK1/4/pan-FLT3 Kinase-IN-2	IRAK	Cancer
IRAK1/4/pan-FLT3 Kinase-IN-2 (compound 27) is a potent *IRAK1/4* and FLT3 dual inhibitor with IC₅₀s of 10, 0.7, and <0.5 nM. IRAK1/4/pan-FLT3 Kinase-IN-2 extends acute myeloid leukemia model mouse survival .

HY-150732

IRAK4-IN-18	IRAK	Inflammation/Immunology
IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease .

HY-120561

PC-046	Trk Receptor IRAK Pim Apoptosis	Cancer
PC-046 is a multi-target inhibitor for *tyrosine receptor kinase* B (TrkB), IRAK-4 and Pim-1, with IC₅₀ of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC₅₀ of 7.5-130 nM. PC-046 induces apoptosis** and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice .

HY-159953A

IRAK1/4/pan-FLT3 Kinase-IN-1 hydrochloride	IRAK FLT3	Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 hydrochloride is an orally active, potent and selective *IRAK/pan-FLT3* *kinase* inhibitor with IC₅₀s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively. IRAK1/4/pan-FLT3 Kinase-IN-1 hydrochloride can be used for research on AML .

HY-103490R

Takinib (Standard) EDHS-206 (Standard)	Reference Standards MAP3K Apoptosis	Infection Inflammation/Immunology Cancer
Takinib (Standard) is the analytical standard of Takinib. This product is intended for research and analytical applications. Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM) .

HY-162538

LC-MI-3	NF-κB IRAK PROTACs	Inflammation/Immunology
LC-MI-3 is an orally active and potent interleukin-1 receptor-associated kinase 4 (IRAK4) PROTAC degrader, with a DC₅₀ of 47.3 nM. LC-MI-3 effectively inhibits the activation of downstream NF-κB signaling. LC-MI-3 can be used for the research of acute and chronic inflammatory skin. (Blue: VHL ligand, Black: linker, Pink: CRBN ligand (HY-14658)) .

HY-180908

IRAK4-IN-34	IRAK	Inflammation/Immunology
IRAK4-IN-34 (compound 19) is a potent, selective, and orally active Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 0.73 nM. IRAK4-IN-34 exhibits good selectivity vs both hERG and other kinases. IRAK4-IN-34 shows favorable in vivo PK properties. IRAK4-IN-34 can be used for inflammatory diseases research .

HY-101922R

IRAK4-IN-1 (Standard)	Reference Standards IRAK	Inflammation/Immunology
IRAK4-IN-1 (Standard) is the analytical standard of IRAK4-IN-1 (HY-101922). This product is intended for research and analytical applications. IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-181712

IRAK1-IN-2	IRAK	Cancer
IRAK1-IN-2 is an orally active *IRAK1* inhibitor and antitumor agent with high selectivity for *IRAK4* and other kinases in the same group. IRAK1-IN-2 functionally inhibits IRAK1 and interferes with the TLR/IL-1R signaling pathway. IRAK1-IN-2 suppresses hepatocellular carcinoma-related cellular processes in vitro and in animal models. IRAK1-IN-2 serves as a chemical probe for IRAK1 research and is applicable to studies on hepatocellular carcinoma .

HY-180579

IRAK4-IN-33	IRAK TNF Receptor IFNAR	Inflammation/Immunology
IRAK4-IN-33 (Compound 22) is a selective, potent and orally active *interleukin-1 receptor-associated kinase* 4** (IRAK4) inhibitor with an IC₅₀ 0.36 nM. IRAK4-IN-33 can block the pro-inflammatory signaling pathway mediated by IRAK4 and inhibit the release of TNFα and IFNα. IRAK4-IN-33 shows weak inhibition for hERG channel (IC₅₀ > 30 μM). IRAK4-IN-33 can be used for the research of inflammation and immunology, such as rheumatoid arthritis .

HY-103017AR

JH-X-119-01 (Standard)	Reference Standards IRAK	Infection Inflammation/Immunology Cancer
JH-X-119-01 (Standard) is the analytical standard of JH-X-119-01 (HY-103017A). This product is intended for research and analytical applications. JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC₅₀ of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .

HY-103017R

JH-X-119-01 hydrochloride (Standard)	Reference Standards IRAK	Infection
JH-X-119-01 hydrochloride (Standard) is the analytical standard of JH-X-119-01 hydrochloride (HY-103017). This product is intended for research and analytical applications. JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice .

Cat. No.	Product Name	Target	Research Area

HY-P5432

IRAK-4 Peptide substrate IRAK-1 (360-380)	IRAK	Others
IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)

Species:	Human (5) Mouse (2)
Tag:	His (5) Tag Free (1) Strep (1) GST (1)
Source:	sf9 insect cells (3) Sf9 insect cells (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701789

	IRAK1 Protein, Human (Active, sf9, GST) IRAK1; Interleukin-1 receptor-associated kinase 1; IRAK-1	Human	Sf9 insect cells
	IRAK1 is a serine/threonine protein kinase that initiates innate immune responses against pathogens through Toll-like receptor (TLR) and IL-1R signaling. After TLR activation, IRAK1 is recruited by MYD88 and undergoes IRAK4 phosphorylation, autophosphorylation, and kinase activation. IRAK1 Protein, Human (sf9, GST) is the recombinant human-derived IRAK1 protein, expressed by sf9 insect cells , with N-GST labeled tag.

HY-P703078

	IRAK4 Protein, Mouse (His) Interleukin-1 receptor-associated kinase 4; IRAK-4; EC:2.7.11.1	Mouse	E. coli
	IRAK4 Protein, Mouse (His) is the recombinant mouse-derived IRAK4, expressed by E. coli , with N-6*His labeled tag. ,

HY-P704729

	IRAK4 Protein, Mouse (Active, Sf9, His) Interleukin-1 receptor-associated kinase 4; IRAK-4; EC:2.7.11.1	Mouse	sf9 insect cells
	IRAK4 Protein, Mouse (Active, Sf9, His) is the recombinant mouse-derived IRAK4 protein, expressed by sf9 insect cells, with N-His tag.

HY-P73255

	IRAK4 Protein, Human (Active, sf9, His) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	Sf9 insect cells
	The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 Protein, Human (Active, sf9, His) is the recombinant human-derived IRAK4 protein, expressed by Sf9 insect cells , with N-10*His labeled tag.

HY-P705844

	IRAK4 Protein, Human (Active, sf9, His-Strep) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	sf9 insect cells

HY-P705845

	IRAK4 Protein, Human (Active, 307a.a, sf9) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	sf9 insect cells

HY-P702732

	IRAK4 Protein, Human (Active, 307a.a, sf9, His) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	Sf9 insect cells
	The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 Protein, Human (307a.a, sf9, His) is the recombinant human-derived IRAK4, expressed by Sf9 insect cells, with His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Rabbit (5)
Reactivity:	Human (5)
Application:	IHC-P (2) ICC/IF (3) IP (3) IHC-F (2) WB (5) FC (1)
Isotype:	IgG (5)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (4) Recombinant (4)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82122

	IRAK2 Antibody (YA1867) Interleukin 1 receptor associated kinase 2; IRAK 2; IRAK2	WB, IP, FC	Human
	IRAK2 Antibody (YA1867) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAK2.

HY-P83307

	IRAKM Antibody (YA3052) IRAK3; Interleukin-1 receptor-associated kinase 3; IRAK-3; IL-1 receptor-associated kinase M; IRAK-M	WB, IP	Human
	IRAKM Antibody (YA3052) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAKM.

HY-P82709

	IRAK-1 Antibody (YA2454) Il1rak; IRAK; IRAK1; IRAK1-S; mPLK; Pelle; Pelle homolog; Pelle-like protein kinase; Plpk	WB, ICC/IF, IP	Human
	IRAK-1 Antibody (YA2454) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAK-1.

HY-P83370

	IRAK4 Antibody (YA3115) IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64	WB, IHC-F, IHC-P, ICC/IF	Human
	IRAK4 Antibody (YA3115) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAK4.

HY-P83370A

	IRAK4 Antibody (YA3115)(PBS only) IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64	WB, IHC-F, IHC-P, ICC/IF	Human
	IRAK4 Antibody (YA3115) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IRAK4.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-137342

SB1-G-187		PROTAC Synthesis
SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, *IRAK1* and LYN. SB1-G-187 induces degradation of target kinases via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: